Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions - ONA

Links shared publicly online about this topic.

  • 380
    total visits

Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions - ONA

oncologynurseadvisor.com

Cuvposa (glycopyrrolate liquid; Shionogi) has been made available for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3--16 years of age.

View full resource at oncologynurseadvisor.com

Tags: Neurology, Cerebral Palsy, Shionogi, Cuvposa

  • Share

Most Recently Shared on April 8, 2011 at 3:44 pm By:

ONAcom OncologyNurseAdvisor

Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions http://goo.gl/fb/vOq8J

1 year ago...

CUVPOSA - New Product Releases - MPR

empr.com — “To reduce chronic severe drooling in patients 3--16yrs of age with neurologic conditions associated with problem drooling (eg, cerebral palsy).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 22, 2011 at 2:31 pm By:

eMPR MPR Medical Publisher

MPR News: CUVPOSA: Glycopyrrolate 1mg/5mL; soln; cherry-flavored. http://bit.ly/fQABRJ

12 months ago...

Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions - MPR

empr.com — “Cuvposa (glycopyrrolate liquid; Shionogi) has been made available for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3--16 years of age.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 8, 2011 at 3:50 pm By:

eMPR MPR Medical Publisher

MPR News: Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions: Cuvposa (glycopyr... http://bit.ly/dEBhht

1 year ago...

Shionogi launches CUVPOSA for pediatric chronic severe drooling

news-medical.net — “Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 2:09 pm By:

NewsMedical News-Medical.Net Health News

Shionogi launches CUVPOSA for pediatric chronic severe drooling: Shionogi Inc., the U.S.-based group company of ... http://bit.ly/gMBd6q

1 year ago...

Cuvposa approved for chronic severe drooling associated with neurologic conditions - MPR

empr.com — “The FDA has approved Cuvposa (glycopyrrolate liquid, from Shionogi), an orphan drug, for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3"16 years of age.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on July 29, 2010 at 4:02 pm By:

eMPR MPR Medical Publisher

MPR News: Cuvposa approved for chronic severe drooling associated with neurologic conditions: The FDA has approved... http://bit.ly/ar1eRe

2 years ago...

Advertisement